AQST 5.80 ▲ 0.52% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Aquestive Therapeutics In...

    NASDAQ: AQST · Real-Time Price · USD
    5.80
    0.03 (0.52%)
    At close: Oct 03, 2025, 3:59 PM
    5.75
    -0.86%
    After-hours: Oct 03, 2025, 07:56 PM EDT
    0.52%
    Bid 5.72
    Market Cap 578.43M
    Revenue (ttm) 44.13M
    Net Income (ttm) -65.04M
    EPS (ttm) -0.69
    PE Ratio (ttm) -8.41
    Forward PE -9.95
    Analyst Buy
    Dividends n/a
    Ask 5.95
    Volume 2,104,294
    Avg. Volume (20D) 2,293,649
    Open 5.77
    Previous Close 5.77
    Day's Range 5.68 - 5.93
    52-Week Range 2.12 - 6.43
    Beta 1.76
    Ex-Dividend Date n/a

    About AQST

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol AQST
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for AQST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Aquestive Therapeutics Inc. is scheduled to release its earnings on Nov 3, 2025, after market closes.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    +28.1%
    Aquestive Therapeutics shares are trading higher a... Unlock content with Pro Subscription
    4 months ago
    -19.65%
    Aquestive Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 sales guidance.
    news image

    2 weeks ago · zacks.com

    Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock?

    Aquestive Therapeutics (AQST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be m...

    news image

    1 month ago · seekingalpha.com

    Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst

    Aquestive Therapeutics's Anaphylm could be the first FDA-approved, non-invasive, orally delivered epinephrine for anaphylaxis, with a PDUFA date set for January 2026. FDA's decision not to convene an ...

    news image

    1 month ago · zacks.com

    AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

    Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.

    news image

    1 month ago · zacks.com

    Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

    Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

    news image

    1 month ago · seekingalpha.com

    Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript

    Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants A. Ernest Toth - Chief Financial Officer Carl N.

    news image

    1 month ago · zacks.com

    Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics

    While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key met...

    news image

    1 month ago · zacks.com

    Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates

    Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.03 per share a year ago.

    Add to Watchlist